Phase 2 N=30 Reclaim Deep Brain Stimulation Clinical Study for Treatment-Resistant Depression
Depression
Primary: Responders — 3; 2 participants — p==0.53
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,830 A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Intraocular Pressure (IOP) in the Study Eye at Baseline — 21.15 Millimeters of Mercury (mmHg)
Phase 3 N=23 Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
Urea Cycle Disorders
Primary: Adverse Events — 0; 6 participants
Phase 4 N=107 Early Whole Blood in Patients Requiring Transfusion After Major Trauma
Trauma/Injury Problem
Primary: Units of Blood Products Required During the First 24 Hours After Emergency Department Admission — 12; 13 units of blood
Phase 4 N=150 Safety Outcomes of Lower Immunosuppression Versus Traditional Immunosuppression in Heart Transplant Recipients
Immunosuppression
Primary: Mean International Society for Heart and Lung Transplantation Biopsy Score Over the First 6 Months Post-transplantation — 0.7; 0.65 units on a scale
Phase 4 N=68 Validation of Dyskinesia Rating Scales
Parkinson's Disease
Primary: The Investigators Will Assess Effect Size With Each Scale for Detecting Change From Baseline and Change Between Amantadine and Placebo; Allowing Assessment of…
N/A N=58 Preservation of Beta-cell Function in Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Primary: Beta-cell Function - C-peptide AUC (Area Under the Curve) — 2096; 1725 ng*min/mL
N/A N=329 Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department
Opiate Addiction
Primary: Self-reported Engagement in Formal Substance Abuse Treatment at 30 Days (Verified by Contact With the Treatment Program) — 4.99; 5.67; 3.71 Mean Number of Outpatient…
N/A N=36 A Prospective Observational Study of Epidural Pressures During Caudal Epidural in the Pediatric Population
Anesthesia, Caudal
Primary: Pressure in the Caudal Epidural Space — 192.5 mmHg
Phase 2 N=30 Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
Poisoning by BCG Vaccine
Primary: Visual Analogue Scale for Pain — 4.5; 4.9; 5.8; 4.2 units on a scale
N/A N=36 Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)
Hypertension · Diabetes
Primary: Change in Systolic Blood Pressure. — 15.37; 10.04; 10.25 mmHg
Phase 2 N=12 Cangrelor Prasugrel Transition Study
Coronary Artery Disease
Primary: Extent of Preservation of Inhibitory Effect After Transition From Cangrelor to Prasugrel Compared With Effect Observed With Prasugrel Alone (Reference Timepoint) — 1.0…
Phase 3 N=15 The Role of Mineralocorticoid Receptors in Vascular Function
Apparent Mineralocorticoid Excess (AME)
Primary: Forearm Blood Flow — 1.87; 1.34 ml/100ml of tissue/min
N/A N=42 Eplerenone for Subclinical Cardiomyopathy in Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Primary: 12-month Change in Myocardial Strain — 2.2; 1.0 percent change in heart dimension
Phase 1 N=28 A Study of Cephalexin in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Cephalexin Following a Single Dose — 77.430; 76.374…